• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在综合性医疗系统专科药房开展、实施和评估健康结果和研究项目。

Development, implementation, and evaluation of a health outcomes and research program at an integrated health-system specialty pharmacy.

机构信息

Specialty Pharmacy Services, Vanderbilt University Medical Center, Nashville, TN, USA.

出版信息

Am J Health Syst Pharm. 2021 May 24;78(11):972-981. doi: 10.1093/ajhp/zxab082.

DOI:10.1093/ajhp/zxab082
PMID:33693451
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8142709/
Abstract

PURPOSE

Health-system specialty pharmacies (HSSPs) provide high-quality, efficient, and collaborative care to patients receiving specialty therapy. Despite proven benefits of the integrated model, manufacturer and payer restrictions challenge the viability and utility of HSSPs. Vanderbilt Specialty Pharmacy developed a health outcomes and research program to measure and communicate the value of this model, drive improvement in patient care delivery, and advocate for recognition of HSSP pharmacists' role in patient care. The purpose of this descriptive report is to describe the development and results of this program.

SUMMARY

The health outcomes and research program began as an initiative for pharmacists to evaluate and convey the benefits they provide to patients, providers, and the health system. Early outcomes data proved useful in communicating the value of an integrated model to key stakeholders and highlighted the need to further develop research efforts. The department leadership invested resources to build a research program with dedicated personnel, engaged research experts to train pharmacists, and fostered internal and external collaborations to facilitate research efforts. As of March 2021, the health outcomes and research program team has published 33 peer-reviewed manuscripts, presented 88 posters and 7 podium presentations at national conferences, and received 4 monetary research awards. Further, the program team engages other HSSP teams to initiate and expand their own health outcomes research in an effort to empower all HSSPs in demonstrating their value.

CONCLUSIONS

The health outcomes and research program described has pioneered outcomes research among HSSPs nationwide and has proven valuable to specialty pharmacists, the health system, and key specialty pharmacy stakeholders.

摘要

目的

医疗系统专科药房(HSSP)为接受专科治疗的患者提供高质量、高效率和协作式的护理。尽管综合模式具有明显的优势,但制造商和支付方的限制对 HSSP 的生存能力和实用性构成了挑战。范德比尔特专科药房制定了一项健康结果和研究计划,以衡量和传达这种模式的价值,推动患者护理服务的改善,并倡导承认 HSSP 药剂师在患者护理中的作用。本报告旨在描述该计划的发展和结果。

摘要

健康结果和研究计划始于药剂师评估并传达他们为患者、医疗服务提供者和医疗系统提供的益处的一项举措。早期的结果数据在向主要利益相关者传达综合模式的价值方面非常有用,并强调了进一步开展研究工作的必要性。部门领导层投入资源建立了一个有专门人员的研究项目,聘请了研究专家对药剂师进行培训,并促进了内部和外部的合作,以促进研究工作。截至 2021 年 3 月,健康结果和研究计划团队已发表了 33 篇同行评议的论文,在全国性会议上展示了 88 篇海报和 7 个演讲,并获得了 4 项研究资金奖励。此外,该计划团队还与其他 HSSP 团队合作,启动和扩大其自身的健康结果研究,努力使所有 HSSP 都能够展示其价值。

结论

所描述的健康结果和研究计划在全国范围内开创了 HSSP 中的结果研究,对专科药剂师、医疗系统和主要专科药房利益相关者都具有重要价值。

相似文献

1
Development, implementation, and evaluation of a health outcomes and research program at an integrated health-system specialty pharmacy.在综合性医疗系统专科药房开展、实施和评估健康结果和研究项目。
Am J Health Syst Pharm. 2021 May 24;78(11):972-981. doi: 10.1093/ajhp/zxab082.
2
Health-system specialty pharmacy role and outcomes: A review of current literature.卫生系统专业药房的作用和结果:对现有文献的回顾。
Am J Health Syst Pharm. 2022 Oct 21;79(21):1906-1918. doi: 10.1093/ajhp/zxac212.
3
2022 ASHP Survey of Health-System Specialty Pharmacy Practice: Clinical Services.2022 年 ASHP 健康系统专业药房实践调查:临床服务。
Am J Health Syst Pharm. 2023 Jun 22;80(13):827-841. doi: 10.1093/ajhp/zxad064.
4
Implementation of an integrated pharmacist collaborative care model in specialty disease state clinics.在专科疾病诊所实施药师综合协作护理模式。
Am J Health Syst Pharm. 2022 Nov 7;79(22):2047-2052. doi: 10.1093/ajhp/zxac209.
5
Droxidopa management by an integrated health-system specialty pharmacy team.综合性医疗系统专科药房团队管理屈昔多巴。
J Am Pharm Assoc (2003). 2022 Nov-Dec;62(6):1904-1911. doi: 10.1016/j.japh.2022.06.002. Epub 2022 Jun 13.
6
Provision of ambrisentan from a health-system specialty pharmacy affiliated with a pulmonary hypertension Center of Comprehensive Care.由一家隶属于综合护理肺动脉高压中心的医疗系统专科药房提供安立生坦。
Am J Health Syst Pharm. 2024 Jan 5;81(2):66-73. doi: 10.1093/ajhp/zxad191.
7
Addressing the Challenges of Novel Oncology and Hematology Treatments Across Sites of Care: Specialty Pharmacy Solutions.应对跨医疗场所的新型肿瘤学和血液学治疗挑战:专科药房解决方案。
J Oncol Pharm Pract. 2022 Apr;28(3):627-634. doi: 10.1177/10781552211072467. Epub 2022 Jan 17.
8
Inclusion in limited distribution drug network reduces time to dalfampridine access in patients with multiple sclerosis at a health-system specialty pharmacy.在医疗系统专科药房中,将药物纳入有限分发网络可减少多发性硬化症患者获得地夫可特的时间。
J Manag Care Spec Pharm. 2021 Feb;27(2):256-262. doi: 10.18553/jmcp.2021.27.2.256.
9
Advancing Patient Care Through Specialty Pharmacy Services in an Academic Health System.在学术医疗系统中通过专业药房服务提升患者护理水平。
J Manag Care Spec Pharm. 2017 Aug;23(8):815-820. doi: 10.18553/jmcp.2017.23.8.815.
10
Adherence to oral oncolytics filled through an internal health-system specialty pharmacy compared with external specialty pharmacies.通过内部医疗系统专科药房与外部专科药房相比,口服肿瘤药物的使用依从性。
J Manag Care Spec Pharm. 2021 Oct;27(10):1438-1446. doi: 10.18553/jmcp.2021.27.10.1438.

本文引用的文献

1
Development of a quality measures tool for the utilization of tyrosine kinase inhibitors in non-small cell lung cancer: An integrated specialty pharmacy initiative.非小细胞肺癌中酪氨酸激酶抑制剂使用的质量衡量工具的开发:一项综合专科药房计划。
J Oncol Pharm Pract. 2020 Sep;26(6):1441-1451. doi: 10.1177/1078155220937754. Epub 2020 Jul 2.
2
An Integrated Health-System Specialty Pharmacy Model for Coordinating Transitions of Care: Specialty Medication Challenges and Specialty Pharmacist Opportunities.一种用于协调医疗护理过渡的综合医疗系统专科药房模式:专科药物挑战与专科药剂师机遇
Pharmacy (Basel). 2019 Dec 3;7(4):163. doi: 10.3390/pharmacy7040163.
3
Risk Factors for Medication Nonadherence to Self-Injectable Biologic Therapy in Adult Patients With Inflammatory Bowel Disease.炎症性肠病成年患者自我注射生物制剂治疗药物不依从的风险因素。
Inflamm Bowel Dis. 2020 Jan 6;26(2):314-320. doi: 10.1093/ibd/izz253.
4
Closing the Gap: Identifying Rates and Reasons for Nonadherence in a Specialty Population.缩小差距:确定特定人群不依从的比率和原因。
J Manag Care Spec Pharm. 2019 Nov;25(11):1282-1288. doi: 10.18553/jmcp.2019.25.11.1282.
5
Development of quality measures for use of self-injectable biologic therapy in inflammatory bowel disease: An integrated specialty pharmacy initiative.炎症性肠病中自我注射生物治疗药物使用的质量措施的制定:一个综合专业药房计划。
Am J Health Syst Pharm. 2019 Sep 1;76(17):1296-1304. doi: 10.1093/ajhp/zxz142.
6
High rates of medication adherence in patients with pulmonary arterial hypertension: An integrated specialty pharmacy approach.肺动脉高压患者的高药物依从率:综合专业药房方法。
PLoS One. 2019 Jun 6;14(6):e0217798. doi: 10.1371/journal.pone.0217798. eCollection 2019.
7
Integrated specialty pharmacy yields high PCSK9 inhibitor access and initiation rates.综合专业药房可提高 PCSK9 抑制剂的可及性和起始治疗率。
J Clin Lipidol. 2019 Mar-Apr;13(2):254-264. doi: 10.1016/j.jacl.2019.01.003. Epub 2019 Jan 14.
8
Adherence to Disease-Modifying Therapies at a Multiple Sclerosis Clinic: The Role of the Specialty Pharmacist.多发性硬化症诊所中对疾病修正疗法的依从性:专科药剂师的作用。
J Pharm Pract. 2020 Oct;33(5):605-611. doi: 10.1177/0897190018824821. Epub 2019 Jan 30.
9
Modeling specialty medicine access: Understanding key health system processes and players.建模专科药物可及性:理解关键的卫生系统流程和参与者。
J Am Pharm Assoc (2003). 2019 Jan-Feb;59(1):43-50.e3. doi: 10.1016/j.japh.2018.09.004. Epub 2018 Nov 8.
10
Increasing success and evolving barriers in the hepatitis C cascade of care during the direct acting antiviral era.直接作用抗病毒药物时代丙型肝炎防治工作的成功率不断提高和障碍不断演变。
PLoS One. 2018 Jun 18;13(6):e0199174. doi: 10.1371/journal.pone.0199174. eCollection 2018.